Advances in the treatment of hemorrhagic stroke: A possible new treatment
Joseph P. Broderick, MD
Professor and Chair, Department of Neurology, University of Cincinnati
Address: Joseph P. Broderick, MD, Professor and Chair of Neurology, University of Cincinnati Medical Center, 231 Albert B. Sabin Way, Cincinnati, OH 45267-0525
The author has indicated that he has received grant or research support from and serves as a consultant for the Novo Nordisk corporation.
Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic Foundation. They are approved by the author but are not peer-reviewed.
ABSTRACTRecombinant factor VIIa may be the first proven treatment for intracerebral hemorrhage (ICH); to be effective, it must be given soon after the onset of symptoms. Surgical removal of the hematoma by craniotomy at about 24 hours does not appear to offer much benefit compared with conservative therapy and delayed surgery, except possibly for superficial ICHs. Standardized management of medical complications remains important. New randomized treatment trials of recombinant factor VII and surgery are in progress or just beginning.